- Previous Close
201.00 - Open
202.00 - Bid 205.00 x --
- Ask 205.50 x --
- Day's Range
201.00 - 206.00 - 52 Week Range
129.20 - 219.50 - Volume
30,240 - Avg. Volume
63,719 - Market Cap (intraday)
30.854B - Beta (5Y Monthly) 1.52
- PE Ratio (TTM)
164.40 - EPS (TTM)
1.25 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield 1.69 (0.84%)
- Ex-Dividend Date Apr 30, 2025
- 1y Target Est
222.11
Medicover AB (publ) provides healthcare and diagnostic services in Poland, India, Romania, Sweden, and internationally. Its Healthcare services includes service outpatient and inpatient care; dental services; other services, including non-medical related services, such as sports memberships, benefit cards, and optics, as well as wellness services; hospital care; and preventive care. The company's Diagnostic Services offers laboratory tests in all major clinical pathology areas, ranging from routine to advanced tests and from prevention to monitoring of treatments. Its also comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. It serves corporate, individuals, and public payers. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.
www.medicover.com47,256
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MCOV-B.ST
View MorePerformance Overview: MCOV-B.ST
Trailing total returns as of 4/14/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MCOV-B.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MCOV-B.ST
View MoreValuation Measures
Market Cap
30.18B
Enterprise Value
42.98B
Trailing P/E
162.09
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.30
Price/Book (mrq)
5.86
Enterprise Value/Revenue
1.86
Enterprise Value/EBITDA
14.01
Financial Highlights
Profitability and Income Statement
Profit Margin
0.80%
Return on Assets (ttm)
2.24%
Return on Equity (ttm)
2.87%
Revenue (ttm)
2.09B
Net Income Avi to Common (ttm)
16.7M
Diluted EPS (ttm)
1.25
Balance Sheet and Cash Flow
Total Cash (mrq)
82.8M
Total Debt/Equity (mrq)
253.20%
Levered Free Cash Flow (ttm)
89M